Switch theme
Sign up to access all valuation multiples
Camurus AB is a research and development-focused pharmaceutical company. It develops pharmaceuticals for the treatment of serious and chronic diseases such as opioid addiction, pain, cancer, and endocrine diseases. The Camurus’ clinical pipeline includes products for the treatment of dependence, pain, cancer and endocrine diseases, which are developed in-house and in collaboration with international pharmaceutical companies. The company's product pipeline includes CAM2029, CAM4072 and CAM2043.
2004
256
LTM Revenue $224M
LTM EBITDA $73.1M
$2.8B
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
Camurus has a last 12-month revenue (LTM) of $224M and a last 12-month EBITDA of $73.1M.
In the most recent fiscal year, Camurus achieved revenue of $193M and an EBITDA of $58.6M.
Camurus expects next 12-month revenue of XXX and NTM EBITDA of XXX
See Camurus valuation multiples based on analyst estimates| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue | $224M | XXX | $193M | XXX | XXX | XXX |
| Gross Profit | $209M | XXX | $179M | XXX | XXX | XXX |
| Gross Margin | 93% | XXX | 93% | XXX | XXX | XXX |
| EBITDA | $73.1M | XXX | $58.6M | XXX | XXX | XXX |
| EBITDA Margin | 33% | XXX | 30% | XXX | XXX | XXX |
| EBIT | $72.5M | XXX | $47.8M | XXX | XXX | XXX |
| EBIT Margin | 32% | XXX | 25% | XXX | XXX | XXX |
| Net Profit | $63.1M | XXX | $44.2M | XXX | XXX | XXX |
| Net Margin | 28% | XXX | 23% | XXX | XXX | XXX |
| Net Debt | XXX | XXX | n/a | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of May 30, 2025, Camurus's stock price is SEK 512 (or $53).
Camurus has current market cap of SEK 30.0B (or $3.1B), and EV of SEK 27.2B (or $2.8B).
See Camurus trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $2.8B | $3.1B | XXX | XXX | XXX | XXX | $1.06 |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Start Free TrialAs of May 30, 2025, Camurus has market cap of $3.1B and EV of $2.8B.
Camurus's trades at 14.6x EV/Revenue multiple, and 47.9x EV/EBITDA.
Equity research analysts estimate Camurus's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Camurus has a P/E ratio of 49.1x.
See valuation multiples for Camurus and 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $3.1B | XXX | $3.1B | XXX | XXX | XXX |
| EV (current) | $2.8B | XXX | $2.8B | XXX | XXX | XXX |
| EV/Revenue | 12.5x | XXX | 14.6x | XXX | XXX | XXX |
| EV/EBITDA | 38.4x | XXX | 47.9x | XXX | XXX | XXX |
| EV/EBIT | 38.7x | XXX | 58.7x | XXX | XXX | XXX |
| EV/Gross Profit | 13.4x | XXX | n/a | XXX | XXX | XXX |
| P/E | 49.1x | XXX | 70.0x | XXX | XXX | XXX |
| EV/FCF | 53.2x | XXX | 75.9x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Start Free TrialCamurus's last 12 month revenue growth is 46%
Camurus's revenue per employee in the last FY averaged $0.8M, while opex per employee averaged $0.5M for the same period.
Camurus's rule of 40 is 79% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
Camurus's rule of X is 148% (created by Bessemer, rule of X is another metric relevant for SaaS companies only, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
See operational valuation multiples for Camurus and other 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue Growth | 46% | XXX | 46% | XXX | XXX | XXX |
| EBITDA Margin | 33% | XXX | 30% | XXX | XXX | XXX |
| EBITDA Growth | 97% | XXX | 36% | XXX | XXX | XXX |
| Rule of 40 | 79% | XXX | 76% | XXX | XXX | XXX |
| Bessemer Rule of X | XXX | XXX | 148% | XXX | XXX | XXX |
| Revenue per Employee | XXX | XXX | $0.8M | XXX | XXX | XXX |
| Opex per Employee | XXX | XXX | $0.5M | XXX | XXX | XXX |
| S&M Expenses to Revenue | XXX | XXX | 26% | XXX | XXX | XXX |
| G&A Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| R&D Expenses to Revenue | XXX | XXX | 37% | XXX | XXX | XXX |
| Opex to Revenue | XXX | XXX | 68% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Julphar | XXX | XXX | XXX | XXX | XXX | XXX |
| Benevolent AI | XXX | XXX | XXX | XXX | XXX | XXX |
| Galapagos | XXX | XXX | XXX | XXX | XXX | XXX |
| Pharming | XXX | XXX | XXX | XXX | XXX | XXX |
| Vivoryon Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Camurus acquired XXX companies to date.
Last acquisition by Camurus was XXXXXXXX, XXXXX XXXXX XXXXXX . Camurus acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Start Free Trial| When was Camurus founded? | Camurus was founded in 2004. |
| Where is Camurus headquartered? | Camurus is headquartered in Sweden. |
| How many employees does Camurus have? | As of today, Camurus has 256 employees. |
| Who is the CEO of Camurus? | Camurus's CEO is Mr. Fredrik Tiberg. |
| Is Camurus publicy listed? | Yes, Camurus is a public company listed on STO. |
| What is the stock symbol of Camurus? | Camurus trades under CAMX ticker. |
| When did Camurus go public? | Camurus went public in 2015. |
| Who are competitors of Camurus? | Similar companies to Camurus include e.g. Julphar, Benevolent AI, Galapagos, Pharming. |
| What is the current market cap of Camurus? | Camurus's current market cap is $3.1B |
| What is the current revenue of Camurus? | Camurus's last 12 months revenue is $224M. |
| What is the current revenue growth of Camurus? | Camurus revenue growth (NTM/LTM) is 46%. |
| What is the current EV/Revenue multiple of Camurus? | Current revenue multiple of Camurus is 12.5x. |
| Is Camurus profitable? | Yes, Camurus is EBITDA-positive (as of the last 12 months). |
| What is the current EBITDA of Camurus? | Camurus's last 12 months EBITDA is $73.1M. |
| What is Camurus's EBITDA margin? | Camurus's last 12 months EBITDA margin is 33%. |
| What is the current EV/EBITDA multiple of Camurus? | Current EBITDA multiple of Camurus is 38.4x. |
| What is the current FCF of Camurus? | Camurus's last 12 months FCF is $52.8M. |
| What is Camurus's FCF margin? | Camurus's last 12 months FCF margin is 24%. |
| What is the current EV/FCF multiple of Camurus? | Current FCF multiple of Camurus is 53.2x. |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
